<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Sinomenine (SN), a bioactive <z:chebi fb="13" ids="22315">alkaloid</z:chebi>, has been utilized clinically to treat <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> in China </plain></SENT>
<SENT sid="1" pm="."><plain>Our preliminary experiments indicated that it could protect PC12 cells from oxygen-<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation-reperfusion (OGD-R), we thus investigated the possible effects of SN on <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> and the related mechanism </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL APPROACH: Middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in rats was used as an animal model of ischaemic <z:hpo ids='HP_0001297'>stroke</z:hpo> in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>The mechanisms of the effects of SN were investigated in vitro using whole-cell patch-clamp recording, calcium imaging in PC12 cells and rat cortical neurons subjected to OGD-R </plain></SENT>
<SENT sid="4" pm="."><plain>KEY RESULTS: Pretreatment with SN (10 and 30 mg·kg(-1) , i.p.) significantly decreased <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> and the overactivation of calcium-mediated events in rats subjected to 2 h <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> followed by 24 h reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>Extracellular application of SN inhibited the currents mediated by acid-sensing ion channel 1a and L-type voltage-gated calcium channels, in the rat cultured neurons, in a concentration-dependent manner </plain></SENT>
<SENT sid="6" pm="."><plain>These inhibitory effects contribute to the neuroprotection of SN against OGD-R and extracellular <z:hpo ids='HP_0001941'>acidosis</z:hpo>-induced cytotoxicity </plain></SENT>
<SENT sid="7" pm="."><plain>More importantly, administration of SN (30 mg·kg(-1) , i.p.) at 1 and 2 h after <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> also decreased <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> and improved functional recovery </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION AND IMPLICATIONS: SN exerts potent protective effects against ischaemic brain injury when administered before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> or even after the injury </plain></SENT>
<SENT sid="9" pm="."><plain>The inhibitory effects of SN on acid-sensing ion channel 1a and L-type calcium channels are involved in this neuroprotection </plain></SENT>
</text></document>